跳至主要内容
临床试验/EUCTR2004-000022-75-IT
EUCTR2004-000022-75-IT进行中(未招募)不适用

Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk.

BRISTOL-M.SQUIBB0 个研究点目标入组 600 人开始时间: 2005年9月30日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
600

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 未提供

研究者

发起方
BRISTOL-M.SQUIBB

相似试验

进行中(未招募)
不适用
Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk - IMPROVEAlbuminuria in hypertensive subjects at increased cardiovascular risk.
EUCTR2004-000022-75-LTBristol-Myers Squibb International Corporation615
进行中(未招募)
1 期
Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Subjects at Elevated Cardiovascular Risk - IMPROVE
EUCTR2004-000022-75-ESBristol-Myers Squibb International Corporation615
进行中(未招募)
不适用
Irbesartan versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Hypertensive Albuminuria in Subjects at Elevated Cardiovascular Risk - IMPROVE
EUCTR2004-000022-75-LVBristol-Myers Squibb International Corporation615
招募中
不适用
Effect of on combination therapy with irbesartan and amlodipine besilate on clinical blood pressure, home blood pressure and blood pressure variability in hypertensive patients with chronic kidney diseaseHypertension with chronic kidney disease (CKD G1-G4)
JPRN-UMIN000013213Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine30
已完成
4 期
Effects of the combination therapy of irbesartan and indapamide in chronik kidney disease with hypertensiochronick kidney disease with hypertension
JPRN-UMIN000010787Division of Nephrology, Department of Internal medicine, Jichi Medical University30